Diagnosis and Treatment of Neurocysticercosis: 2017 Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH)

被引:74
作者
White, A. Clinton, Jr. [1 ]
Coyle, Christina M. [2 ]
Rajshekhar, Vedantam [3 ]
Singh, Gagandeep [4 ]
Hauser, W. Allen [5 ]
Mohanty, Aaron [1 ]
Garcia, Hector H. [6 ,7 ]
Nash, Theodore E. [8 ]
机构
[1] Univ Texas Med Branch, Galveston, TX 77555 USA
[2] Albert Einstein Coll Med, Bronx, NY 10467 USA
[3] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India
[4] Dayanand Med Coll, Ludhiana, Punjab, India
[5] Columbia Univ, New York, NY USA
[6] Inst Nacl Ciencias Neurol, Lima, Peru
[7] Univ Peruana Cayetano Heredia, Lima, Peru
[8] NIH, Bldg 10, Bethesda, MD 20892 USA
关键词
LINKED IMMUNOELECTROTRANSFER BLOT; SOLITARY CYSTICERCUS GRANULOMA; ENDOSCOPIC 3RD VENTRICULOSTOMY; TERM ANTIEPILEPTIC TREATMENT; ENHANCING CT LESION; DOUBLE-BLIND; CEREBRAL CYSTICERCOSIS; ALBENDAZOLE THERAPY; FOLLOW-UP; HYDROCEPHALUS SECONDARY;
D O I
10.4269/ajtmh.18-88751
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Guidelines for the clinical management of patients with neurocysticercosis (NCC) were prepared by a panel of the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). The guidelines are intended for infectious disease specialists, neurologists, neurological surgeons, internists, pediatricians, and family practitioners. These guidelines present our approaches to the diagnosis and management of patients with the different forms of NCC, including viable parenchymal NCC (VPN), single enhancing lesions (SEL), calcified parenchymal NCC (CPN), ventricular NCC (IVN), and subarachnoid NCC (SAN). Our recommendations are based on the best evidence available. Because of the complex variations in clinical manifestations and the limitations of the literature, many of the recommendations are based on observational studies, anecdotal data, or expert opinion rather than randomized clinical trials. The approaches we describe are intended to be both applicable and feasible in the United States and Canada (for simplicity, referred to here as North America). The recommendations may not apply for settings where resource constraints may limit their applicability. The executive summary in the following paragraphs lists the recommendations for the diagnosis and clinical management of NCC. A detailed description of the methods, background, and evidence summaries that support each of the recommendations can be found online in the full text of the guidelines. A criterion for grading evidence is presented in Figure 1.1 Note that diagnosis and management of patients with NCC can be challenging even with expert guidelines. Because of this complexity, clinicians with little experience with this disease should have a low threshold for consultation with an expert in the disease. © 2018 by The American Society of Tropical Medicine and Hygiene.
引用
收藏
页码:945 / 966
页数:22
相关论文
共 153 条
  • [1] Focal limb dystonia in a patient with a cerebellar mass
    Alarcón, F
    Tolosa, E
    Muñoz, E
    [J]. ARCHIVES OF NEUROLOGY, 2001, 58 (07) : 1125 - 1127
  • [2] CEREBRAL CYSTICERCOSIS AS A RISK FACTOR FOR STROKE IN YOUNG AND MIDDLE-AGED PEOPLE
    ALARCON, F
    VANORMELINGEN, K
    MONCAYO, J
    VINAN, I
    [J]. STROKE, 1992, 23 (11) : 1563 - 1565
  • [3] CEREBRAL CYSTICERCOSIS AND STROKE
    ALARCON, F
    HIDALGO, F
    MONCAYO, J
    VINAN, I
    DUENAS, G
    [J]. STROKE, 1992, 23 (02) : 224 - 228
  • [4] Concurrent asymptomatic inflammatory aneurysm and ischemic stroke due to cysticercal arteritis
    Arauz, Antonio
    Ruiz-Navarro, Francisco
    Silos, Humberto
    Camilo Vargas-Gonzalez, Juan
    Arguelles-Morales, Nayelli
    Reyes, Marisela
    Ruiz-Franco, Angelica
    Rivera, Aleyda
    Fleury, Agnes
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2013, 115 (12) : 2540 - 2542
  • [5] Evidence-based guideline: Treatment of parenchymal neurocysticercosis Report of the Guideline Development Subcommittee of the American Academy of Neurology
    Baird, Ruth Ann
    Wiebe, Sam
    Zunt, Joseph R.
    Halperin, John J.
    Gronseth, Gary
    Roos, Karen L.
    [J]. NEUROLOGY, 2013, 80 (15) : 1424 - 1429
  • [6] EXTRAPARENCHYMAL NEUROCYSTICERCOSIS - REPORT OF 5 CASES AND REVIEW OF MANAGEMENT
    BANDRES, JC
    WHITE, AC
    SAMO, T
    MURPHY, EC
    HARRIS, RL
    [J]. CLINICAL INFECTIOUS DISEASES, 1992, 15 (05) : 799 - 811
  • [7] Large cerebral infarction during praziquantel therapy in neurocysticercosis
    Bang, OY
    Heo, JH
    Choi, SA
    Kim, DI
    [J]. STROKE, 1997, 28 (01) : 211 - 213
  • [8] Frequency of cerebral arteritis in subarachnoid cysticercosis -: An angiographic study
    Barinagarrementeria, F
    Cantú, C
    [J]. STROKE, 1998, 29 (01) : 123 - 125
  • [9] NEUROCYSTICERCOSIS AS A CAUSE OF STROKE
    BARINAGARREMENTERIA, F
    CANTU, C
    [J]. STROKE, 1992, 23 (08) : 1180 - 1180
  • [10] Bayer, PROD INF BILTR PRAZ